A novel chemistry platform that targets toxic protein mis‑assembly in neurodegenerative and metabolic diseases.

The initial focus of the Pangomer approach is on neurodegenerative diseases, including Parkinson’s and Alzheimer’s. There are many opportunities for expansion into other classes of disease.

A Pangomer analogue optimized for selectivity to non-amyloid forms of islet amyloid polypeptide (IAPP) shows good pharmacological properties in a mouse model of Type II Diabetes.

Pangolin Therapeutics, Inc.

Connecticut Innovations provides strategic capital and operational insight to push the frontiers of high-tech industries such as energy, biotechnology, information technology, and photonics. Over the years, CI has helped over 100 emerging companies research, develop, and market new products and services. This activity has attracted over $1 billion dollars in additional investments from private equity providers. CI has brought the State of Connecticut over $510 million in Gross State Profit and over 5,000 additional job-years.

Career Opportunities